BioSpace News Archive

Policy

Cautiously Stepping Into the Future of AI by Stepping Back Into the Past at DIA’s MASC

GenAI, the youngest of the AI family, is evolving quickly. The global life sciences industry is attempting to evolve with it. However, as a keynote session at DIA’s MASC suggests, taking a pause to understand AI risks and to prepare to comply with the EU AI Act is what is needed.

March 19, 2024
·
5 min read
·
Lori Ellis
Drug Development

Bayer’s Veozah Rival Hits Goals in Long-Term Phase III Hot Flash Study

Bayer bagged another late-stage victory for its menopause drug candidate Tuesday, setting up a potential showdown with Astellas’ Veozah which was approved last year by the FDA for the treatment of hot flashes.

March 19, 2024
·
2 min read
·
Nick Paul Taylor
Drug Development

Historic Approval for MASH, CAR-Ts in the Spotlight

The FDA took center stage last week as it approved the first-ever MASH therapy and considered additional approvals for CAR-T therapies, whose safety the agency has been investigating since last year.

March 19, 2024
·
1 min read
·
Greg Slabodkin, Heather McKenzie, Tyler Patchen
Policy

Regeneron Wins Appeal in Eylea-Lucentis Antitrust Case Against Novartis

An appellate court sided with Regeneron versus Novartis on Monday, agreeing that anti-VEGF pre-filled syringes constitute a distinct market than those sold in vials. The case involves Regeneron’s Eylea and Novartis’ Lucentis eye treatments.

March 19, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch

To help support the launch of Lyfgenia, bluebird bio on Monday entered into a five-year term loan deal with Hercules Capital that will extend the biotech’s cash runway through the first quarter of 2026.

March 19, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission

The biotech Tuesday reported that 56% of patients taking paltusotine in a late-stage trial achieved the primary endpoint of IGF-1 levels for their rare hormonal disorder. An NDA submission is slated for later this year with a launch anticipated in 2025.

March 19, 2024
·
1 min read
·
Kate Goodwin
Career Advice

With the Salary Growth Rate Slowing, Should Biopharma Employees Look for New Jobs?

The past year saw the slowest year-over-year growth in biopharma salaries in the past five years, according to the BioSpace 2024 Life Sciences Salary Report.

March 19, 2024
·
6 min read
·
Angela Gabriel
FDA

Orchard Wins FDA Approval for First Gene Therapy for Rare Pediatric Disease

Orchard Therapeutics on Monday secured the FDA’s first approval for an autologous gene therapy to treat the rare metabolic disease metachromatic leukodystrophy in children.

March 19, 2024
·
2 min read
·
Tristan Manalac
Deals

AstraZeneca Buys Fusion in Potential $2B Deal, Joins Radiopharma Buying Spree

Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.

March 19, 2024
·
3 min read
·
Tristan Manalac
Drug Development

Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward

Engrail Therapeutics’ latest financing round will give it enough funds to advance its candidates for neuropsychiatric and neurodevelopmental disorders through clinical development.

March 19, 2024
·
2 min read
·
Tyler Patchen